James E Garrett

US Patent:

6727226, Apr 27, 2004

Filed:

Jul 23, 2001

Appl. No.:

09/910009

Inventors:

Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
James E. Garrett - Salt Lake City UT
Lourdes J. Cruz - Manila, PH
Robert M. Jones - Salt Lake City UT
G. Edward Cartier - Salt Lake City UT
John D. Wagstaff - Salt Lake City UT

Assignee:

University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT

International Classification:

C07K 708

US Classification:

514 13, 514 2, 530326, 530300

Abstract:

The present invention is to -conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the -conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The -conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the -conopeptides and encoding propeptides, as well as the propeptides.

US Patent:

6767896, Jul 27, 2004

Filed:

May 26, 2000

Appl. No.:

09/580201

Inventors:

J. Michael McIntosh - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
Lourdes J. Cruz - Manila, PH
Gloria P. Corpuz - Miliani HI
Robert M. Jones - Salt Lake City UT
James E. Garrett - Salt Lake City UT

Assignee:

Cognetix, Inc. - Salt Lake City UT
University of Utah Research Foundation - Salt Lake City UT

International Classification:

A61K 3808

US Classification:

514 14, 514 2, 514 15, 530324, 530327, 530300

Abstract:

The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.

US Patent:

7115708, Oct 3, 2006

Filed:

Aug 8, 2005

Appl. No.:

11/198847

Inventors:

Robert M. Jones - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US

Assignee:

University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT

International Classification:

C07K 4/12
A61K 51/08

US Classification:

530324, 424 169

Abstract:

The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the β-superfamily conotoxin peptides and encoding β-superfamily conotoxin propeptides, as well as the β-superfamily conotoxin propeptides.

US Patent:

7238513, Jul 3, 2007

Filed:

Aug 31, 2005

Appl. No.:

11/216937

Inventors:

Grzegorz Bulaj - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Olga Buczek - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US
Ian Goodsell - Sandy UT, US

Assignee:

University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT

International Classification:

C12N 9/00
C12N 9/90
C07H 21/04
C12P 21/06

US Classification:

435233, 435183, 435 691, 435 681, 4353201, 435325, 435419, 4352523, 43525411, 536 232

Abstract:

Protein disulfide isomerase is a major component of venom ducts. The invention relates to a protein disulfide isomerase (PDI) from snails, a nucleic acid sequence encoding the protein disulfide isomerase, and to methods for folding disulfide-rich peptides using a protein disulfide isomerase. Oxidative folding of conotoxin precursors, catalyzed by a PDI, was more efficient and decreased the number and concentration of transiently accumulated folding species. The PDI-assisted oxidative folding of conotoxins was also influenced by the propeptide relative to the mature peptide.

US Patent:

7368432, May 6, 2008

Filed:

Jul 19, 2004

Appl. No.:

10/893300

Inventors:

J. Michael McIntosh - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Lourdes J. Cruz - Sta. Mesa, PH
Gloria P. Corpuz - Miliani HI, US
Robert M. Jones - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US

Assignee:

Xenome, Ltd. - Queensland
Cognetix, Inc. - Salt Lake City UT

International Classification:

A61K 38/08
A61K 38/17
C07K 7/06
C07K 14/435

US Classification:

514 15, 514 12, 530857, 530327, 530324

Abstract:

The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.

US Patent:

7262280, Aug 28, 2007

Filed:

Oct 3, 2000

Appl. No.:

09/679664

Inventors:

Thomas M. Stormann - Salt Lake City UT, US
Lance G. Hammerland - Salt Lake City UT, US
Laura L. Storjohann - Salt Lake City UT, US
James G. Busby - Simi Valley CA, US
James E. Garrett - Salt Lake City UT, US
Rachel T. Simin - Durham NC, US

Assignee:

NPS Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

C07K 1/00
C08H 1/00
C07H 21/04
C12P 21/06
C12N 1/20

US Classification:

530402, 530350, 536 234, 536 235, 435 691, 4352523, 4353201, 435325, 435471

Abstract:

The present invention features G-protein fusion receptors and chimeric GABAreceptors (GABARs), nucleic acid encoding such receptors, and the use of such receptors and nucleic acid. G-protein fusion receptors comprise at least one domain from a CaR, an mGluR, and/or a GABAreceptor fused directly or through a linker to a guanine nucleotide-binding protein (G-protein). Chimeric GABARs comprise at least one of a GABAR extracellular domain, a GABAR transmembrane domain, or a GABAR intracellular domain and one or more domains from a mGluR subtype 8 (mGluR8) and/or a CaR.

US Patent:

20020198145, Dec 26, 2002

Filed:

Jul 20, 2001

Appl. No.:

09/908739

Inventors:

Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US

Assignee:

COGNETIX, INC. - Salt Lake City UT

International Classification:

A61K038/17

US Classification:

514/012000

Abstract:

The present invention is directed to the new O-conopeptides, their coding sequences and their propeptides and to the use of O-conopeptides as a local anesthetic for treating pain. The O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.

US Patent:

20030065138, Apr 3, 2003

Filed:

Mar 7, 2002

Appl. No.:

10/092367

Inventors:

Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake CIty UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US

Assignee:

University of Utah Research Foundation - Salt Lake City UT

International Classification:

C07K007/08
C07K014/435

US Classification:

530/324000, 530/326000, 530/327000

Abstract:

The invention relates to linear -carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.